STAAD, Switzerland--(BUSINESS WIRE)--Biosynth, a global supplier of critical raw materials and services to the life sciences industry, today announced that its Board of Directors has appointed Matt Gunnison as the company's new Chief Executive Officer and a member of the Board of Directors, effective immediately.

瑞士斯塔德——（商业新闻短讯）——全球生命科学行业关键原材料和服务供应商Biosynth今天宣布，其董事会已任命马特·甘尼森为公司新任首席执行官和董事会成员，立即生效。

The Board has also appointed Kieran Murphy as Chairman, effective as of the same date..

董事会还任命基兰·墨菲为董事长，自同日起生效。。

Matt Gunnison will succeed Urs Spitz, under whose guidance Biosynth has achieved remarkable growth and strengthened its position in the life sciences sector. Urs Spitz will remain a member of the Board of Directors.

马特·甘尼森（Matt Gunnison）将接替乌尔斯·斯皮茨（Urs Spitz），在他的指导下，Biosynth取得了显著的增长，并巩固了其在生命科学领域的地位。Urs Spitz将继续担任董事会成员。

“We are grateful to Urs for his significant contributions in shaping Biosynth into the innovative and thriving company it is today. We are now excited to welcome Matt as CEO, whose vision and extensive experience will be pivotal in leading the company through its next chapter,” said Kugan Sathiyanandarajah, Partner at KKR and Head of Europe for KKR’s Health Care Strategic Growth strategy..

KKR合伙人兼KKR医疗保健战略增长战略欧洲负责人Kugan Sathiyanandarajah表示：“我们非常感谢Urs在将Biosynth打造成今天这家创新且蓬勃发展的公司方面所做出的重大贡献。我们现在很高兴欢迎Matt担任首席执行官，他的远见和丰富的经验将对领导公司度过下一个篇章至关重要。”。。

“I am thrilled to join Biosynth at such an exciting time in its journey. The company has built a strong foundation under Urs’s leadership, and I look forward to working with the talented team to further accelerate our growth and innovation. Together, we will continue to deliver critical raw materials and services that drive advancements in the life sciences and make a real impact on global health outcomes,” said Matt Gunnison..

马特·甘尼森（Matt Gunnison）表示：“我很高兴在Biosynth旅程中如此激动人心的时刻加入。该公司在Urs的领导下奠定了坚实的基础，我期待着与人才团队合作，进一步加速我们的增长和创新。我们将继续提供关键的原材料和服务，推动生命科学的进步，并对全球健康产生真正的影响。”。。

“It’s a privilege to be appointed Chairman of Biosynth. I am excited to work alongside Matt and the entire team as we chart the course for the company’s continued growth. Biosynth is at the forefront of innovation in the life sciences industry, and I am confident we have the right leadership and vision to drive our success forward,” said Kieran Murphy..

。。

“I’m immensely proud of what Biosynth has accomplished. I would like to congratulate Matt and Kieran on their new roles and wish them, along with the whole Biosynth team, great success in the years ahead. I look forward to continuing to support them in my role on the Board as they lead Biosynth into this new chapter,” said Urs Spitz..

乌尔斯·斯皮茨（Urs Spitz）说：“我为Biosynth取得的成就感到无比骄傲。我要祝贺马特（Matt）和基兰（Kieran）担任新角色，并祝愿他们以及整个Biosynth团队在未来几年取得巨大成功。我期待着在他们带领Biosynth进入这一新篇章的过程中，继续支持他们担任董事会的角色。”。。

Matt currently serves as CEO of Gamma Biosciences, a life sciences investment platform that he co-founded with leading global investment firm KKR. He brings nearly two decades of experience in the healthcare and life sciences industries. At Gamma, Matt oversaw the acquisition and management of a portfolio of growth stage businesses serving the biopharmaceutical manufacturing industry.

马特目前担任伽玛生物科学公司（Gamma Biosciences）的首席执行官，伽玛生物科学公司是他与全球领先的投资公司KKR共同创建的生命科学投资平台。他在医疗保健和生命科学行业拥有近二十年的经验。。

Prior to Gamma, he served in various positions at GE Healthcare, most recently as head of corporate development for the $19B division of General Electric Co. Matt holds a B.A. in Economics from Georgetown University and a J.D. from the University of Michigan..

在加入Gamma之前，他曾在GE Healthcare担任过多个职位，最近一次担任通用电气（General Electric Co.）190亿美元部门的企业发展主管。Matt拥有乔治敦大学（Georgetown University）的经济学学士学位和密歇根大学（University of Michigan）的法学博士学位。。

Kieran currently serves as a senior advisor to KKR and will transition to Biosynth from Gamma Biosciences, where he has served as Chairman since 2022. He brings decades of corporate leadership and board experience in healthcare and life sciences, including as former President and CEO of GE Healthcare and GE Healthcare Life Sciences..

Kieran目前担任KKR的高级顾问，并将从Gamma Biosciences过渡到Biosynth，他自2022年以来一直担任主席。他在医疗保健和生命科学领域拥有数十年的企业领导和董事会经验，包括担任GE healthcare和GE healthcare life sciences的前总裁兼首席执行官。。

Joining Matt and Kieran, as Head of Corporate Development for Biosynth, is Eric Simpson, previously Vice President at Gamma Biosciences.

加入马特和基兰（Matt and Kieran）的是生物同步公司（Biosynth）企业发展负责人埃里克·辛普森（EricSimpson），他曾任伽玛生物科学公司（Gamma Biosciences）副总裁。

About Biosynth

关于Biosynth

Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing, and distribution facilities. Supplying the pharmaceutical and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation.

Biosynth是关键材料的供应商，通过全球研究，制造和分销设施确保生命科学供应链的安全。为制药和诊断部门提供服务；在化学与生物、产品与服务、创新与质量的结合中，Biosynth处于创新的边缘。

With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides, and Key Biologics, all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners and management.

Biosynth拥有超过100万种产品的无与伦比的研究产品组合和端到端的制造服务，其专业知识和能力涵盖了复杂的化学品、肽和关键生物制剂，所有这些都来自一个值得信赖的合作伙伴。Biosynth总部位于瑞士斯塔德，由KKR、安培生资本合伙人和管理层拥有。

Find out more about Biosynth at www.biosynth.com..

。。

About KKR

关于KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities.

KKR是一家领先的全球投资公司，提供替代资产管理以及资本市场和保险解决方案。KKR的目标是通过遵循耐心和自律的投资方法，雇佣世界一流的人才，并支持其投资组合公司和社区的增长，从而产生有吸引力的投资回报。

KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries.

KKR赞助投资于私人股本、信贷和房地产的投资基金，并拥有管理对冲基金的战略合作伙伴。KKR的保险子公司在全球大西洋金融集团的管理下提供退休、人寿和再保险产品。提及KKR的投资可能包括其赞助基金和保险子公司的活动。

For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com..

有关KKR&Co.Inc.（纽约证券交易所代码：KKR）的更多信息，请访问KKR的网站www.KKR.com。有关全球大西洋金融集团的更多信息，请访问全球大西洋金融集团的网站www.globalatlantic.com。。

About Ampersand

关于Ampersand

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams.

安倍资本合伙公司（AmpersandCapitalPartners）成立于1988年，是一家中等市场私人股本公司，管理着30亿美元的资产，致力于医疗保健领域的增长型投资。安倍在马萨诸塞州波士顿和荷兰阿姆斯特丹设有办事处，利用私募股权和运营经验的独特融合，与投资组合公司管理团队一起创造价值并推动长期业绩。

Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit Ampersandcapital.com or follow Ampersand on LinkedIn..

Ampersand帮助在公司的每个核心医疗保健部门建立了众多市场领先的公司。有关更多信息，请访问Ampersandcapital.com或在LinkedIn上关注Ampersand。。